Patrick Lin - 01 Oct 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Business - Strategy Off
Issuer symbol: PCSA
Report date: 01 Oct 2025
Net transaction value: $0
Form type: 4
Accepted by SEC: 03 Oct 2025, 16:31:12 UTC
Previous filing: 18 Sep 2025
Next filing: 04 Feb 2026
SEC filing: View on sec.gov
Reporting owner signature: /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact

Key filing fact

Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 03 Oct 2025.

Key facts

This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Oct 2025, 16:31.

Change

Previous filing in this sequence was filed on 18 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001799363 Primary reporting owner

Lin Patrick

Relationship: Chief Business - Strategy Off
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Signature date: 03 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +68,000
Change %
Price: $0.000000
Shares after: 68,000
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 68,000
Exercise price: $0.000000
Footnotes: F1

PCSA transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +204,000
Change %
Price: $0.000000
Shares after: 204,000
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 204,000
Exercise price: $0.1980
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.

Footnote F2

Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.